Clinical Trials Arena November 1, 2024
Jenna Philpott

The role of emerging digital tools and AI were at the forefront of a panel discussion at the Outsourcing in Clinical Trials DACH 2024 conference.

As the role of technology and digital tools in clinical trials expands, industry leaders are grappling with how to balance innovation with ethical and regulatory safeguards.

Speaking at the Outsourcing in Clinical Trials (OCT) DACH 2024 conference in Zurich, Switzerland on 29-30 October, a panel weighed in on the challenges of integrating new digital tools – ranging from AI to wearables – in ways that are both effective and ethical.

“There is a lot of awareness from the regulators now that this has to be moved forward,” said Eva Herrmann-Keiner, senior clinical operations manager at...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), Clinical Trials, Technology, Trends
Related Articles:
Is SOAR Obsolete? Here’s Why Security Engineers And AI Make The Difference
Vanderbilt University Medical Center expanding use of ambient AI
Health AI: How Apple can boost public health
AI In Payments: Opportunities, Challenges And Best Practices
AI in healthcare: What to expect in 2025

Share This Article